Rituximab + Lenalidomide + Valemetostat
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma
Trial Timeline
May 19, 2023 → Sep 30, 2027
NCT ID
NCT05683171About Rituximab + Lenalidomide + Valemetostat
Rituximab + Lenalidomide + Valemetostat is a phase 1/2 stage product being developed by Daiichi Sankyo for Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05683171. Target conditions include Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05683171 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Lymphoma